APLM
Apollomics Inc. Class A Ordinary Shares
NASDAQ: APLM · HEALTHCARE · BIOTECHNOLOGY
$13.08
+1.75% today
Updated 2026-04-29
Market cap
$28.71M
P/E ratio
—
P/S ratio
3.19x
EPS (TTM)
$-7.57
Dividend yield
—
52W range
$4 – $40
Volume
0.0M
Apollomics Inc. Class A Ordinary Shares (APLM) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $1.84M | $2000.00 | $323000.00 | $821000.00 | $198000.00 | $8.50M |
| Revenue growth (YoY) | — | — | -99.9% | +16050.0% | +154.2% | -75.9% | +4192.9% |
| Cost of revenue | $369000.00 | $609000.00 | $681000.00 | $775000.00 | $694000.00 | $361000.00 | — |
| Gross profit | $-369000.00 | $1.84M | $2000.00 | $323000.00 | $821000.00 | $198000.00 | — |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 0.0% |
| R&D | $18.44M | $31.44M | $35.57M | $35.46M | $34.19M | $24.57M | $5.53M |
| SG&A | — | $11.04M | $15.29M | $9.95M | $20.64M | $17.77M | $12.44M |
| Operating income | $-24.75M | $-40.65M | $-50.86M | $-45.08M | $-54.01M | $-42.14M | $-9.19M |
| Operating margin | — | -2211.4% | -2542850.0% | -13957.0% | -6578.9% | -21280.8% | -108.2% |
| EBITDA | $-45.34M | $-40.51M | $-50.12M | $-43.88M | $-53.45M | $-41.05M | — |
| EBITDA margin | — | -2204.0% | -2505850.0% | -13586.1% | -6509.9% | -20734.8% | 0.0% |
| EBIT | $-45.71M | $-40.65M | $-50.27M | $-44.06M | $-53.55M | $-41.13M | — |
| Interest expense | $46000.00 | $72000.00 | $83000.00 | $93000.00 | $150000.00 | $179000.00 | $65000.00 |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-45.91M | $-74.82M | $-94.80M | $-240.81M | $-172.60M | $-53.86M | $-10.94M |
| Net income growth (YoY) | — | -63.0% | -26.7% | -154.0% | +28.3% | +68.8% | +79.7% |
| Profit margin | — | -4070.7% | -4739850.0% | -74554.5% | -21023.3% | -27201.0% | -128.7% |